Evidence map›Paper›PMID 39812189›Full record

ArticleLa Tunisie medicale2025

High performance COVID-19 screening using machine learning.

Youssef Zied Elhechmi, Mehdi Mrad, Mariem Gdoura, Anissa Nouri, Helmi Ben Saad, Najla Ghrairi, Henda Triki

Abstract read
In one paragraph

Article in La Tunisie medicale, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Youssef Zied ElhechmiHope Horizon International.
Mehdi MradLaboratory of viruses, vectors and hosts: LR20IPT10, Institut Pasteur de Tunis, University of Tunis El Manar, 13, Place Pasteur, 1002 Tunis Belvédère, Tunisia.
Mariem GdouraLaboratory of Clinical Virology, Institut Pasteur de Tunis, University of Tunis El Manar, 13, Place Pasteur, 1002 Tunis-Belvédère, Tunisia.
Anissa NouriClinical investigation center: 2016CICIPT02, Institut Pasteur de Tunis, University of Tunis El Manar, 13, Place Pasteur, 1002 Tunis Belvédère, Tunisia.
Helmi Ben SaadMD (Faculty of Medicine of Sousse, Tunisia). PhD (Faculty of Medicine of Montpellier, France). Physiology and Functional Explorations. Laboratory of Physiology and Functionnal Explorations. Farhat Havhed Hospital. Sousse, Tunisia. Laboratory of Physiology. Faculty of Medicine of Sousse. Street Mohamed Karoui. Sousse 4000. Tunisia.
Najla GhrairiHope Horizon International.
Henda TrikiLaboratory of viruses, vectors and hosts: LR20IPT10, Institut Pasteur de Tunis, University of Tunis El Manar, 13, Place Pasteur, 1002 Tunis Belvédère, Tunisia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the World Health Organization declared the Coronavirus Disease 2019 (COVID-19) pandemic as an international concern of public health emergency in the early 2020, several strategies have been initiated in many countries to prevent healthcare services breakdown and collapse of healthcare structures. The most important strategy was the increased testing, diagnosis, isolation, contact tracing to identify, quarantine and test close contacts. In this context, finding a rapid, reliable and affordable tool for COVID-19 screening was the main challenge to address the pandemic. Molecular diagnosis by reverse transcriptase polymerase chain reaction (RT-PCR), even though considered as the gold standard in the diagnosis of COVID-19, was time consuming and therefore does not fit the objective of rapid screening. In addition, serological tests to detect anti-severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) antibodies suffered from low sensitivity. Prediction models based on machine-learning (ML) that combined several clinical features to estimate the risk of COVID-19 have been developed. To address these screening challenges, we created a ML model (MLM) based on gradient boosting method. We included several clinical features and the daily geographic prevalence of COVID-19 cases in the MLM. The MLM was trained on 1554 cases (757 COVID-19), and tested on 547 cases (169 COVID-19). Our MLM successfully predicted RT-PCR positivity with an accuracy of 97.06%. Moreover, the variable sensitivity and specificity of our MLM depending on the disease geographic prevalence has introduced the concept of "dynamic" disease screening. In the context of future world pandemic emergencies, we believe that this MLM method can be very useful as a rapid, reliable and dynamic screening tool for contagious diseases, especially in the developing countries.

Indexed as

COVID-19COVID-19 TestingMachine LearningMass ScreeningAdultFemaleHumansMaleMiddle AgedSARS-CoV-2Sensitivity and SpecificityArtificial intelligenceCOVID-19Machine learningMass screeningPublic health

Identifiers

PMID39812189
PMCPMC11906240

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.